BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
A definitive Manual for Internet Mastering and Expertise Improvement - 2German Winemakers Rewrite The Rules Of Riesling In A Warming World
- 3Real time features for Films and Programs
- 4Jillian Michaels put me at the center of a body positivity debate. She's not entirely wrong about obesity.
- 5A top Marine shares his secrets to keeping fit at 50
- Figure out How to Advance Space in Your Pre-assembled Home for Upgraded Usefulness
- Promising Speculation Bearings for Portfolio Development in 2024
- India's top court hears challenges to ruling on women's entry into temple
- New research reveals urban raccoons across the US show early signs of domestication
- New dietary guidelines recommend more dairy, meat and fats: What to know
- Iran-backed Iraqi militias attack Kurdistan over 450 times since beginning of war
- Native Americans had dice and games of probability long before other cultures, study finds
- What an expert on the gut microbiome eats in a day
- Live long and loiter: Why NASA's ESCAPADE probes will wait a year in space before heading to Mars
